Investigation of Serum Seladin-1/DHCR24 Levels in Breast Cancer Patients

ABSTRACT

Objective: Seladin-1, an enzyme that catalyzes the cholesterol formation reaction from desmosterol, has been shown to be expressed at different levels in various types of tumor. The purpose of this study was to investigate the relationship between serum seladin-1 levels and clinical characteristics of patients with non-metastatic breast cancer, and to examine the prognostic value of seladin-1 in breast cancer.

Methods: Patients aged 18 and over diagnosed with breast cancer using histopathological methods at our medical oncology clinic, whose tumor tissue had been surgically removed and who had not yet received any oncological treatment, and with no distant organ metastasis or additional malignancy, and healthy women volunteers as a control group were included in the study. Demographic and laboratory data were recorded. Serum seladin-1 levels were compared between the patient and control groups.

Results: Seventy-three women, 46 patients and 27 controls, were enrolled. Mean ages were 56±12 years in the patient group and 62±12 years in the control group (p=0.055). Seladin-1 levels were lower in the patient group than in the control group (p=0.038). No statistically significant relationship was observed between tumor size and seladin-1 levels (p=0.138). No relationship was also determined between patient grades and stages and seladin-1 (p=0.720; p=0.092, respectively).

Conclusions: Seladin-1 levels were lower in the serum of breast cancer patients than in the control group. However, no statistically significant relationship was found between breast cancer prognostic factors and seladin-1 levels. Further research is needed to clarify the mechanisms underlying the low seladin-1 levels in breast cancer patients.

Keywords: Breast Cancer, Seladin-1, DHCR24, Prognostic Value

Meme Kanserli Hastalarda Serum Seladin-1/DHCR24 Düzeyinin Araştırılması

ÖZET

Amaç: Meme kanseri kadınlarında önemli bir morbidite ve mortalite nedenidir. Desmosterolden kolesterol oluşum reaksiyonunu katalizleyen enzim olan Seladin-1 daha önce çeşitli tümör türlerinde farklı düzeylerde exprese edildiği göstermiştir. Çalıştırmamızda; serum seladin-1 düzeyleri ile metastatik olmayan meme kanseri hastalarının klinik özellikleri arasındaki ilişkiyi ve seladin-1’in meme kanserinde prognostik değeri araştırmayı amaçladık.

Gereç ve Yöntem: Tibbi onkoloji klinigimizde, 18 yaş üstü, histopatolojik olarak meme kanseri tanıtılan, cerrahi olarak tümör dokusu çıkarılan, herhangi bir onkolojik tedavi henüz almasa, uzak organ metastazı ve ek malignitesi olmayan hastalar ile kontrol grubu olarak seçilmiş 73 kadının çalışmaya dahil edildi. Demografik veriler ve laboratuvar verileri kaydedildi. Serum seladin-1 düzeyleri hasta ve kontrol grupları arasında karşılaştırıldı.

Bulgular: 46 hasta ve 27 kontrol grubu olmak üzere toplam 73 kadın hasta çalışmaya dahil edildi. Hasta grubunun yaş ortalaması 56±12 yıl, kontrol grubunun 62±12 yıldır (p=0.055). Seladin-1 düzeyleri gruplar arasında karşılaştırıldığında; hasta grubunda kontrol grubuna göre daha düşük seviyede saptandı (p=0.038). Tümör boyutları ile Seladin-1 düzeyi arasında istatistiksel bir ilişki yoktu (p=0.138). Bunun yanı sıra, hastaların stage ve gradelerine göre seladin-1 düzeyi karşılaştırıldığında istatistiksel farklı olduğu görülmedi (p=0.720; p=0.092, sırasıyla).

Sonuç: Çalıştırmamızda meme kanseri hastalarının serumlarında seladin-1 düzeyi kontrol grubuna göre daha düşük saptandı. Ne var ki, meme kanserinin prognostik faktörleri ile seladin-1 düzeylerinin ilişkili olduğu görülmüştür. Seladin-1’in meme kanserli hastalarda düşük olmasının alta yatan mekanizmaların aydınlatılabilmesi için daha ileri araştırmalar gerekmekteidir.

Anahtar Kelimeler: Meme Kanseri, Seladin-1, DHCR24, Prognostik Değer
INTRODUCTION
Breast cancer is the most frequent cancer and the second major cause of cancer-related deaths in women (1, 2). The global prevalence of breast cancer is also increasing. However, despite this increase, survival rates have improved continually in recent years thanks to intensive research and new therapeutic modalities (3, 4). However, survival rates and quality of life can also decrease significantly once failure in treatment occurs. Finding a reliable prognostic factor capable of improving survival is therefore of great importance.

Selective Alzheimer Disease Indicator-1 (Seladin-1), also known as DHCR24 for 24-dehydrocholesterol reductase, is an enzyme that catalyzes cholesterol formation from desmosterol (5). The name derives from its being less expressed in brain specimens from Alzheimer’s patients compared to healthy individuals (6). It has also been found to prevent neuron degeneration in the brain with its anti-apoptotic functions (7). Seladin-1 is a multifunctional protein expressed by the DHCR24 gene. It is associated with oxidative stress, cell proliferation, anti-apoptotic, and anti-inflammatory effects (8). Seladin-1 acts by inhibiting activation of caspase 3, an important apoptosis modulator (9). DHCR24 was determined to be associated with cell differentiation and senescence in a study of DHCR24 gene knockout mice (10). However, the cytoprotective mechanisms of seladin-1 have not been fully explained. For example, the response to acute and chronic oxidative stress differs. In acute oxidative stress seladin-1 expression is up-regulated by increasing intracellular cholesterol synthesis, while in chronic oxidative stress it is down-regulated (11). Due to the cytoprotective effect of seladin-1, its role in various cancers has also been investigated, including melanoma, adrenal cancer, bladder cancer, pituitary tumors, prostate cancer, and endometrium cancer (12-17). However, seladin-1 has been observed to be expressed at different levels in these cancer types compared to normal tissues.

The aim of this study was to investigate the prognostic value of serum seladin-1 by analyzing its levels and the clinical features of patients with non-metastatic breast cancer.

MATERIAL AND METHODS
Participants: Forty-six patients aged 18 and over diagnosed with breast cancer using histopathological methods at the Duzce University Medical Faculty Medical Oncology Clinic, whose tumor tissue had been surgically removed and who had not yet received any oncological treatment, and with no distant organ metastasis or additional malignancy, and 27 healthy women were included in the study.

Individuals aged under 18, pregnant women, and individuals with additional malignancy, distant organ metastasis, and acute or chronic infection were excluded. Informed consent forms were obtained from all participants. Demographic data and laboratory parameters of both groups were analyzed.

Sample Collection and Biochemical Analysis: Blood samples were collected following 12-14 h fasting. Serum was separated by centrifugation for 10 min at 4000 rpm. Routine parameters were investigated using photometric methods at the Biochemistry Laboratory Research Hospital with the help of an IDS B0728 auto Seladin-1 levels were determined using a commercially available ELISA kit (ABIN1129410, Biocompare, Georgia) with spectrophotometric methods. Concentrations of seladin-1 in samples were determined by comparison of ODs against a standard curve at 250 nm.

Statistical Analysis: Statistical analyses were performed on SPSS (Statistical Package for Social Sciences) for Windows 22 software. The Kolmogorov–Smirnov test was employed to assess the distribution of variables. Results were expressed as mean ± standard deviation and median (min-max). P data were compared using the independent-samples t-test in case of parametric parameters, or using the Mann-Whitney U test for non-parametric parameters. The chi-square or Fisher exact tests were applied for the comparison of qualitative data. p<0.05 was regarded as statistically significant.

Ethics: This study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants before enrollment. The study protocols and consent forms were approved by the ethics committee of the Duzce University Medical Faculty (approval number: 2019/136).

RESULTS
Seventy-three women, 46 patients and 27 controls were included in this study. The mean ages were 56±12 years in the patient group and 62±12 in the control group (p=0.055). Body mass index values were 30.60±5.49 kg/m² in the patient group and 29.43±4.23 kg/m² in the control group (p=0.374). No statistically significant difference was determined in lipid parameters between the groups (p>0.05). Seladin-1 levels were lower in the patient group than in the control group (0.28461±0.10181 ng/ml vs 0.40530±0.15130 ng/ml respectively, p=0.038). Basic characteristics and laboratory parameters of the patient and control groups are summarized in Table 1.
A family history of breast cancer was present in 20 patients (43.5%), but not in 26 (54.3%) (p=0.698). There was no statistically significant association between tumor size and seladin-1 levels (p=0.138). In addition, no statistically significant difference was observed when seladin-1 levels were compared in terms of patients’ grades and stages (p=0.720 and p=0.092, respectively). A comparison of patients’ seladin-1 levels and clinicopathological characteristics is summarized in Table 2.

Table 2. Relations between patients’ clinicopathological factors and seladin-1

| Characteristic | n (%) | Serum seladin-1 level, median (min-max) | P |
|----------------|-------|----------------------------------------|---|
| Age            |       |                                        |   |
| ≤45 y          | 10 (21.7) | 0.2507 (0.1164-0.3309) | .456 |
| >45 y          | 36 (78.3)  | 0.2430 (0.1977-1.6006) |   |
| Family History |       |                                        |   |
| Positive       | 20 (43.5)  | 0.2451 (0.1977-1.6006) | .698 |
| Negative       | 26 (54.5)  | 0.2437 (0.1164-0.4961) |   |
| Tumor size     |       |                                        |   |
| T1             | 21 (45.7)  | 0.2373 (0.1977-0.2978) |   |
| T2             | 22 (47.8)  | 0.2455 (0.1164-1.6006) | .138 |
| T3             | 3 (6.5)    | 0.3046 (0.2391-0.3654) |   |
| Metastatic LMP |       |                                        |   |
| Positive       | 12 (26)    | 0.2438 (0.2217-0.3654) | 1.000 |
| Negative       | 34 (74)    | 0.2472 (0.1977-1.6006) |   |
| Stage          |       |                                        |   |
| I              | 15 (32.6)  | 0.2381 (0.1977-0.2978) |   |
| II             | 15 (32.6)  | 0.2437 (0.1986-1.6006) | .720 |
| III            | 16 (34.8)  | 0.2455 (0.1164-0.3654) |   |
| Grade          |       |                                        |   |
| I              | 3 (7.7)    | 0.2250 (0.2225-0.2824) | .092 |
| II             | 27 (69.2)  | 0.2431 (0.1977-0.3309) |   |
| III            | 9 (23.1)   | 0.2629 (0.1986-0.4961) |   |
| ER             |       |                                        |   |
| Positive       | 39 (84.8)  | 0.2439 (0.1164-1.6006) | .771 |
| Negative       | 7 (15.2)   | 0.2431 (0.1986-0.4961) |   |
| PR             |       |                                        |   |
| Positive       | 38 (82.6)  | 0.2443 (0.1160-1.6006) | .908 |
| Negative       | 8 (17.4)   | 0.2357 (0.1986-0.4961) |   |
| CERBB2         |       |                                        |   |
| Positive       | 18 (39.1)  | 0.2434 (0.1164-0.4961) | .770 |
| Negative       | 28 (60.9)  | 0.2443 (0.2102-1.6006) |   |
| Ki-67          |       |                                        |   |
| <14%           | 14 (32.6)  | 0.2438 (0.2102-0.3135) | .876 |
| ≥14%           | 29 (67.4)  | 0.2431 (0.1164-0.4961) |   |
| LVI            |       |                                        |   |
| Positive       | 24.53.3    | 0.2443 (0.1977-0.3654) | .802 |
| Negative       | 21 (46.7)  | 0.2431 (0.1164-1.6006) |   |
| PNI            |       |                                        |   |
| Positive       | 12 (26.1)  | 0.2530 (0.1164-0.3654) | .230 |
| Negative       | 34 (73.9)  | 0.2430 (0.2211-1.6006) |   |

ER=estrogen receptor, PR=progesterone receptor
The area under the curve (AUC: 0.651) for seladin-1 was analyzed in all groups to confirm whether seladin-1 serum level may be a reliable predictor of breast cancer. The cut-off point identified for seladin-1 was 0.2735 ng/mL, and this exhibited 75% sensitivity, 59.2% specificity, a 76.5% positive predictive value (PPV), and a 57.1% negative predictive value (NPV) at receiver operator characteristic (ROC) analyses (p=0.031). The results are shown in Figure 1.

|          | AUC   | Cut-off | Sensitivity | Spesivity | PPV   | NPV   | P       |
|----------|-------|---------|-------------|-----------|-------|-------|---------|
|          | 0.651 | 0.2735  | 75%         | 59.2%     | 76.5% | 57.1% | 0.031*  |

Figure 1. ROC analysis of seladin-1 levels between the patient and control groups

DISCUSSION

Our findings revealed lower serum seladin-1 in breast cancer patients than in the control group. Nonetheless, prognosis did not vary in line with serum seladin-1 levels. The present research is the first study to investigate seladin-1 in patient serum.

DHCR24, an enzyme that catalyzes cholesterol formation from desmosterol, was given the name seladin-1 due to its being downregulated from the brains of Alzheimer’s patients and to its neuroprotective characteristics (18). Seladin-1 expressed at high levels from brain cells has also been shown to exhibit a protective role against oxidative stress-related neuron apoptosis (9, 14, 19). Seladin-1 is expressed at varying levels from different tissues and tumors (20, 21). It also contributes significantly to cell survival and death regulation (22).

The role of seladin-1 in various types of cancer has also previously been investigated. In one such study, Wu et al. determined a high level of upregulation of endogenous seladin-1 levels in oxidative stress (23). One noteworthy finding in that study was that seladin-1 is also associated with the tumor suppressor gene p53. Seladin-1 binds to the p53 amino terminal following exposure to oncogenic and oxidative stress, and displaces E3 ubiquitin ligase Mdm2 from p53, thus leading to p53 accumulation. Additionally, in the light of these data, seladin-1 was shown to prevent senescence Ras/p53-mediated oncogenic signaling supporting the tumor suppression role of p53 (23).

A defect in seladin-1 converted into cholesterol from desmosterol can result in impairment of the lipid cell membrane, free radical activation, and thus cell death (24, 25). One striking piece of evidence for this is ‘desmosterolosis syndrome,’ a rare autosomal recessive entity characterized by desmosterol accumulation in the body and progressing with severe multiple congenital anomalies developing due to seladin-1 gene mutation. Lipid profiles in this study were similar between the patient and control groups since we anticipated that these might affect seladin-1 levels.

Serum seladin-1 levels were lower in the patient group in the present study. Luciani et al. compared seladin-1 levels in adrenal carcinoma, adrenal adenoma, and normal adrenal gland groups and observed lower seladin-1 levels in the adrenal carcinoma group than in the other groups (26). In another study involving adrenal carcinoma, Simi et al. also reported significantly lower seladin-1 mRNA expression in adrenal carcinomas compared to normal adrenal glands (27). Battista et al.
investigated the relationship between prostate cancer and seladin-1 and reported that seladin-1 expression increased in low-risk prostate cancer while decreasing in advanced prostate cancer (28). They attributed this to seladin-1 expression increasing in order to inhibit cell proliferation as the first stages of cancer develop (low-grade, Gleason grade 3), with this increase probably being in order to slow the progression of the cancer. However, seladin-1 is no longer able to interfere with the progression of high grade (Gleason grade 4 and 5) cancer, with seladin-1 expression being too low to decrease as other factors leading to progression of the cancer assume control. This is also supported by Kuehnle et al.’s study of the response of seladin-1 to acute and chronic oxidative stress. Those authors determined that seladin-1 is up-regulated in acute stress, but gives a downregulated response in long-term oxidative stress. Those authors attributed this to acute and chronic responses to oxidative stress. Mol Cell Bio

There are several limitations to the present study. Our patient number was low. It would also have been useful to have examined response seladin-1 levels following administration of oncological therapy. In addition, had long-term follow-up been performed an association might have been shown between prognosis and seladin levels depending on whether patients were metastatic or not. However, our patients consisted of newly diagnosed and not yet treated non-metastatic individuals. In addition, seladin levels being lower in the patient group compared to the control group despite the surgical removal of the tumor burden, may also be important in terms of monitoring the benefit of adjuvant oncological therapies.

CONCLUSION

To the best of our knowledge, this is the first study to investigate seladin-1 levels in human serum using ELISA. Selain-1 levels were lower in serum from breast cancer patients compared to the control group, but no association was observed between seladin-1 levels and cancer progression. There is a strong link between seladin-1 and cancer, but this association depends on the type and course of the cancer. Further research is therefore needed to clarify the underlying mechanism involved in the lower serum seladin-1 levels observed in breast cancer patients.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
2. Wollschläger D, Meng X, Wöckel A, Janni W, Kreienberg R, Blettner M, et al. Comorbidity-dependent adherence to guidelines and survival in breast cancer. Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. The breast journal 2018;24:120-7.
3. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017;67:439-48.
4. Marcon M, Dedes K, Varga Z, Frauenfelder T, Boss A. Influence of breast cancer opportunistic screening on aesthetic surgical outcome: A single-center retrospective study in Switzerland. The breast journal 2018;24:285-90.
5. Drzewinska J, Pulaski L, Soszynski M, Bartosz G. (Seladin-1/DHCR24: a key protein of cell homeostasis and cholesterol biosynthesis). Postepy Hig Med Dosw (Online) 2009;63:318-30.
6. Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, et al. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer’s disease. Neuroscience 2002;113:301-10.
7. Waterham HR, Koster J, Remeijn GJ, Hennekam RC, Vreken P, Andersson HC, et al. Mutations in the 3β-hydroxysterol Δ24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. The Am J Hum Genet 2001;69:685-94.
8. Lu X, Li Y, Wang W, Chen S, Liu T, Jia D, et al. 3 β-hydroxysteroid-Δ 24 reductase (DHCR24) protects neuronal cells from apopototic cell death induced by endoplasmic reticulum (ER) stress. PloS one 2014;9:e86753.
9. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J Neuroscience 2000;20:7345-52.
10. Mirza R, Hayasaka S, Takagishi Y, Kambe F, Ohmori S, Maki K, et al. DHCR24 gene knockout mice demonstrate lethal dermatopathy with differentiation and maturation defects in the epidermis. J Invest Derma 2006;126:638-47.
11. Kuehnle K, Cramer A, Kälin RE, Luciani P, Benvenuti S, Peri A, et al. Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Bio 2008;28:539-50.
12. Doherty SC, McKeown SR, Lopez JA, Walsh IK, McKelvey-Martin VJ. Gene expression in normal urothelium depends on location within the bladder: a possible link to bladder carcinogenesis. Eur Urol 2006;50:290-301.

13. Sarkar D, Imai T, Kambe F, Shibata A, Ohmori S, Siddiq A, et al. The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. J Clin Endoc Metab 2001;86:5130-7.

14. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, et al. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endoc Metab 2005;90:6156-61.

15. Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, et al. Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Laboratory investigation 2008;88:1049.

16. Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E, et al. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Inter J Cancer 2005;115:224-30.

17. Dai M, Zhu X-L, Liu F, Xu Q-Y, Ge Q-L, Jiang S-H, et al. Cholesterol synthetase DHCR24 induced by insulin aggravates cancer invasion and progesterone resistance in endometrial cancer. Sci Report 2017;7:41404.

18. Cramer A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, et al. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. Embo J 2006;25:432-43.

19. Benvenuti S, Luciani P, Vannelli GB, Gelmini S, Franceschi E, Serio M, et al. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer’s disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J Clin Endoc Metab 2005;90:1775-82.

20. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388-93.

21. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Nat Acad Sci 2002;99:4465-70.

22. Benvenuti S, Luciani P, Cellai I, Deledda C, Baglioni S, Saccardi R, et al. Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors. J Endoc 2008;197:437-46.

23. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004;432:640.

24. Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer’s disease AβP (1–40) and (1–42) peptides. FASEB J. 2002;16:1526-36.

25. Sista F, Abruzzese V, Clementi M, Carandina S, Amicucci G. Effect of resected gastric volume on ghrelin and GLP-1 plasma levels: a prospective study. J Gastrointes Sur 2016;20:1931-41.

26. Luciani P, Ferruzzi P, Arnaldi G, Crescioli C, Benvenuti S, Nesi G, et al. Expression of the novel adrenocorticotropic-responsive gene selective Alzheimer’s disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endoc Metab 2004;89:1332-9.

27. Simi L, Malentacchi F, Luciani P, Gelmini S, Deledda C, Arvia R, et al. Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC cancer 2010;10:201.

28. Battista MC, Guimond MO, Roberge C, Doueiik AA, Fazli L, Gleave M, et al. Inhibition of DHCR24/Seladin-1 impairs cellular homeostasis in prostate cancer. The Prostate 2010;70:921-33.